H.B. Fuller ($FUL): 8 Directors Buy $1.12M in Stock—What Do They Know? 🧪💰

At $49.56, the adhesives specialist trades near multi-year valuation lows while directors accumulate shares, profits improve and management targets higher-margin markets. Is Wall Street missing something?

H.B. Fuller

NYSE: FUL | October 9, 2026, 4:10 PM ET

$49.56 | −$0.88 (−1.74%)

🧪 Something Sticky Is Happening on Wall Street

Industrial adhesives aren't exactly the sexiest corner of the stock market.

Nobody throws cocktail parties to discuss sealants. Few investors dream about polyurethane chemistry.

But H.B. Fuller ($FUL) has been quietly holding the world together since 1887.

Literally.

Its adhesives, coatings and specialty chemicals appear in everything from packaging and medical devices to electronics, aerospace and construction.

And lately, something rather unusual has happened.

Eight directors bought shares in the open market within roughly two weeks.

The CEO had already purchased nearly $300,000 worth in April.

Meanwhile, earnings are improving, margins are expanding and the stock is trading at a compressed valuation.

Is this a classic value opportunity—or are insiders underestimating the risks?

Let's examine the evidence.

⚛️ FUNanc1al Atomic Statements

“When eight directors independently put personal capital behind the same company within days, the signal deserves attention. The investment case still has to survive the balance sheet.” — FUNanc1al

“The most interesting value opportunities emerge when operational performance improves faster than the market's willingness to pay for it.” — FUNanc1al

“A cheap earnings multiple becomes compelling only when the earnings are sustainable and the debt financing them remains manageable.” — FUNanc1al

💰 1. The Insider Buying Cluster: Eight Directors, One Message

Between September 28 and October 7, eight H.B. Fuller directors purchased shares at approximately $49–$50.

Combined director purchases: approximately $1.12 million.

And there's more.

CEO Celeste Mastin purchased 5,170 shares at $57.08 on April 7, investing approximately $295,104.

Together, the eight recent director purchases and the CEO's earlier transaction represent approximately $1.42 million.

At $49.56, the stock trades about 13% below the CEO's April purchase price.

Investors entering today therefore pay less per share than Mastin did—but that doesn't automatically make today's purchase attractive.

The intriguing element is the breadth of participation.

Eight directors independently choosing to increase their exposure is unusual enough to warrant investigation.

Still, we should distinguish the transactions from stock awards or routine compensation and avoid assuming that coordinated timing necessarily means coordinated conviction.

FunStock signal: Strongly positive.

📈 2. Earnings: The Business Is Improving

H.B. Fuller's third-quarter fiscal 2026 results were substantially better than the share-price trend might suggest.

Adjusted EPS exceeded consensus expectations around $1.46–$1.47.

More importantly, the company achieved a record adjusted EBITDA margin of 19.9%.

Management attributed much of the improvement to pricing execution and restructuring savings.

Here's the interesting detail: pricing increased revenue by 7.4%, offsetting declining volumes.

That's evidence of pricing power—but also a reminder that underlying demand isn't firing on every cylinder.

Full-year adjusted EPS guidance was narrowed to $4.70–$4.85, while adjusted EBITDA guidance stands at $655M–$670M.

The earnings story is improving.

The question is whether volume growth will eventually join the party.

💵 3. Valuation: Has the Market Overreacted?

At approximately $49.56, a recent valuation snapshot suggests:

The forward earnings multiple is particularly interesting.

A company generating 21% adjusted EPS growth and record adjusted margins isn't typically associated with a single-digit forward P/E.

Of course, one quarter doesn't establish a permanent earnings trajectory.

And a stock can remain cheap for excellent reasons.

The crucial question is whether H.B. Fuller can sustain margins, improve volumes and reduce leverage while continuing its specialty-products strategy.

Cheap is interesting. Cheap plus improving fundamentals is more interesting.

🏦 4. Institutions Own More Than 100%?

According to a recent ownership snapshot, institutional holdings amount to approximately 106.63% of outstanding shares.

No, Wall Street hasn't discovered a way to manufacture extra H.B. Fuller stock in a laboratory.

Institutional ownership figures can exceed 100% because of reporting-date mismatches, overlapping classifications, securities lending and short-selling mechanics.

They should not be interpreted as literal ownership of more shares than exist.

BlackRock reportedly held approximately 15.44%, with Vanguard-related entities, State Street, Dimensional and other institutional investors also represented.

The institutional presence is substantial, although index-fund ownership shouldn't be confused with active bullish conviction.

Meanwhile, short interest was approximately 5.46%, with around 3.21 days to cover in the examined September snapshot.

That's meaningful skepticism—not a GameStop-style short-squeeze setup.

For H.B. Fuller ($FUL)'s institutional ownership breakdown, 🔍 see here.

🏗️ 5. The Balance Sheet: Progress, Not Perfection

H.B. Fuller ended Q3 with approximately $1.96 billion in net debt.

Net debt to adjusted EBITDA improved from 3.3× to 3.0× year over year.

That's movement in the right direction.

Year-to-date operating cash flow increased 17% to $183 million.

But leverage remains material.

The company's market capitalization is roughly $2.7 billion, while enterprise value is substantially higher because of its debt and other enterprise-value adjustments.

A cheap equity multiple alone doesn't capture that financial burden.

Further acquisitions could complicate deleveraging.

This is particularly relevant to the company's proposed acquisition of Advanced Medical Solutions, which would expand its medical adhesives exposure.

The strategic logic is attractive.

The financing, integration and execution risks must still be assessed.

👉 Want the full picture? Dive into H.B. Fuller ($FUL)'s financials here.

🩹 6. The Higher-Margin Specialty Adhesives Strategy

CEO Celeste Mastin is pushing H.B. Fuller toward more specialized, higher-margin markets.

Medical technology, electronics, aerospace and other technically demanding applications offer opportunities for differentiated products and closer customer relationships.

The company is also pursuing manufacturing consolidation, productivity improvements and digital transformation.

Those initiatives can support margins even when industrial volumes remain sluggish.

But the transition takes time, and acquisitions must generate returns above their financing and integration costs.

In the meantime, investors are watching a business whose operational progress appears stronger than its share-price momentum.

⚠️ 7. What Could Go Wrong?

Three risks dominate.

First, volume weakness. Pricing has supported revenue, but sustained growth eventually requires healthy customer demand.

Second, leverage. At 3.0× net debt to adjusted EBITDA, financial flexibility is improving but remains constrained.

Third, acquisition execution. Medical adhesives could enhance the product mix, but large transactions can increase complexity and debt.

There is also a fourth consideration: the stock's technical trend remains weak.

Buying a fundamentally improving business doesn't guarantee an immediate market re-rating.

Sometimes the falling knife simply keeps falling.

Industrial glue is strong. Market gravity can be stronger.

💡💡💡 Curious about another deep oil exploration play? (joke)
Check our takes on UnitedHealth Group or even Oscar Health.

H.B. Fuller — Methodology Scorecard schematic

📌 Signal Extract

“When eight directors independently put personal capital behind the same company within days, the signal deserves attention. The investment case still has to survive the balance sheet.” — FUNanc1al

🎯 High-Conviction Takeaway

“The most interesting value opportunities emerge when operational performance improves faster than the market's willingness to pay for it.” — FUNanc1al

⚡ Quick Take / TL;DR

H.B. Fuller presents an intriguing combination of broad director buying, 21% adjusted EPS growth, record adjusted EBITDA margins and a forward P/E near 10×.

The balance sheet is improving, but leverage remains substantial. Volume weakness and acquisition execution are the principal risks.

FunStock Index™: 8.0/10 — Attractive value setup, with meaningful balance-sheet and execution risks.

❓ FAQ

Why are H.B. Fuller insiders buying shares?

Their individual motivations aren't disclosed. The purchases suggest willingness to increase personal exposure, but they do not prove that the stock is undervalued.

How much did insiders purchase?

Eight directors purchased approximately $1.12 million in late September and early October. Including the CEO's April purchase brings the total to roughly $1.42 million.

Is H.B. Fuller profitable?

Yes. The company reported $79 million in Q3 net income and $1.44 in GAAP diluted EPS.

Why does institutional ownership exceed 100%?

Reporting differences, share lending, short positions and ownership-data methodology can produce figures above 100%. It doesn't mean institutions literally own more shares than exist.

What is the biggest investment risk?

Leverage and its interaction with industrial demand, acquisitions and cash generation.

Does H.B. Fuller pay a dividend?

Yes. The yield is approximately 1.9%, although the current declaration and yield should be verified by investors considering buying shares.

🌎 Food for Thought: The Cross-Hub Connection

H.B. Fuller connects an astonishing range of industries.

Medical adhesives help secure devices and support specialized healthcare applications.

Packaging adhesives help protect and transport food and consumer goods.

Engineering adhesives help assemble electronics, vehicles and industrial equipment.

The common theme?

Small, highly specialized materials can make enormous systems work.

In investing, the same principle applies.

Sometimes the most important companies aren't the ones consumers recognize.

They're the ones holding everything together.

Literally.

Carpe Diem!